Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Empliciti (elotuzumab)
i
Other names:
BMS-901608, HuLuc63, PDL063, BMS901608, BMS 901608, HuLuc-63, PDL 036, PDL-063
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(8)
News
Trials
Company:
AbbVie, BMS
Drug class:
CS-1 inhibitor
Related drugs:
‹
RXDX-105 (5)
PVX-410 (0)
SLAMF7 FPBMC (0)
RXDX-105 (5)
PVX-410 (0)
SLAMF7 FPBMC (0)
›
Associations
(8)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
pomalidomide + elotuzumab
Sensitive: A1 - Approval
pomalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
lenalidomide + elotuzumab
Sensitive: A1 - Approval
lenalidomide + elotuzumab
Sensitive
:
A1
lenalidomide + elotuzumab
Sensitive: A1 - Approval
lenalidomide + elotuzumab
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
bortezomib + elotuzumab
Sensitive: A2 - Guideline
bortezomib + elotuzumab
Sensitive
:
A2
bortezomib + elotuzumab
Sensitive: A2 - Guideline
bortezomib + elotuzumab
Sensitive
:
A2
Chr del(17p)
Multiple Myeloma
Chr del(17p)
Multiple Myeloma
lenalidomide + elotuzumab
Sensitive: B - Late Trials
lenalidomide + elotuzumab
Sensitive
:
B
lenalidomide + elotuzumab
Sensitive: B - Late Trials
lenalidomide + elotuzumab
Sensitive
:
B
Chr t(14;16)
Multiple Myeloma
Chr t(14;16)
Multiple Myeloma
lenalidomide + elotuzumab
Sensitive: C3 – Early Trials
lenalidomide + elotuzumab
Sensitive
:
C3
lenalidomide + elotuzumab
Sensitive: C3 – Early Trials
lenalidomide + elotuzumab
Sensitive
:
C3
Chr t(4;14)
Multiple Myeloma
Chr t(4;14)
Multiple Myeloma
lenalidomide + elotuzumab
Sensitive: C3 – Early Trials
lenalidomide + elotuzumab
Sensitive
:
C3
lenalidomide + elotuzumab
Sensitive: C3 – Early Trials
lenalidomide + elotuzumab
Sensitive
:
C3
CD20 underexpression
Multiple Myeloma
CD20 underexpression
Multiple Myeloma
elotuzumab
Resistant: D – Preclinical
elotuzumab
Resistant
:
D
elotuzumab
Resistant: D – Preclinical
elotuzumab
Resistant
:
D
CCL20 underexpression
Multiple Myeloma
CCL20 underexpression
Multiple Myeloma
elotuzumab
Sensitive: D – Preclinical
elotuzumab
Sensitive
:
D
elotuzumab
Sensitive: D – Preclinical
elotuzumab
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login